Organotin (IV) Dithiocarbamate Compounds as Potential Anticancer Agents: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Nurul Amalina Abd Aziz
,
Normah Awang
,
Kok Meng Chan
,
Nurul Farahana Kamaludin
,
Nur Najmi Mohamad Anuar

Organotin (IV) dithiocarbamate has recently received attention as a therapeutic agent among organotin (IV) compounds. The individual properties of the organotin (IV) and dithiocarbamate moieties in the hybrid complex form a synergy of action that stimulates increased biological activity. Organotin (IV) components have been shown to play a crucial role in cytotoxicity. The biological effects of organotin compounds are believed to be influenced by the number of Sn-C bonds and the number and nature of alkyl or aryl substituents within the organotin structure. Ligands target and react with molecules while preventing unwanted changes in the biomolecules. Organotin (IV) dithiocarbamate compounds have also been shown to have a broad range of cellular, biochemical, and molecular effects, with their toxicity largely determined by their structure.

  • organotin (IV)
  • dithiocarbamate
  • synthesis
  • characterization
  • cytotoxicity

1. Background Chemistry of Organotin (IV) Dithiocarbamate

Tin, a group 14 post-transition metal, exists in two main oxidation states: tin (II) and tin (IV) [1]. Nevertheless, most of the known tin compounds are organotin (IV) derivatives, which are relatively more stable than their +II state, readily oxidized to their +IV state, and frequently polymerized [2]. Organotin compounds are formed when tin (Sn) bonds with carbon (C) atoms [3][4][5]. A general formula for these compounds is RxSn(L)4−x, where R represents an alkyl (such as methyl, ethyl, propyl, or butyl) or aryl (such as phenyl) group and L represents an organic or inorganic ligand [6][7]. Organotin compounds can be categorized based on the number of organic moieties on the Sn atom as mono-substituted, di-substituted, tri-substituted, or tetra-substituted (Figure 1) [6][8][9][10].
Molecules 28 05841 g001 550
Figure 1. Structure of organotin (IV) compounds.
The dithiocarbamate anions with the generic formula -S2CNR′R″ (Figure 2) are the semi-amides of dithiocarbonic acids and sulfur analogs of carbamates (R2NCO2-) [11][12][13][14]. Since the 1940s, dithiocarbamates have been used as non-systemic pesticides to treat various fungal diseases in numerous crops and ornamental plants [15]. Moreover, these compounds and their derivatives are active agents in pharmacology, medicine, and biochemistry, and are extensively used in inorganic and organic chemistry. Their stability and interesting electrochemical and optical properties render them a valuable tool in research [16]. Previous studies have reported that the two donor sulfur atoms contribute significantly to the metal-binding capabilities of dithiocarbamate ligands [12][17]. These compounds possess well-known ligands that can firmly and selectively bind to a wide range of metal ions [12][18], making them extremely useful for a variety of medicinal and industrial applications.
Molecules 28 05841 g002 550
Figure 2. Structure of dithiocarbamate.
The local geometry around the Sn (IV) atom is affected by the chelation mode and coordination number of the dithiocarbamates [11][19]. Additionally, the binding properties of the metal ions determine the structure of the resulting metal complexes [17][20]. Dithiocarbamate can coordinate with the tin atom, relying on the coordination number of the Sn (IV) atom, which ranges from four to seven [11][19]. These compounds are bidentate (two S atoms bonded to the central metal atom or ion), anisobidentate bridging (one S atom bonded to the metal ion and the other S atom bridged to an adjacent molecule, forming dissimilar Sn-S bond distances), or monodentate (one S atom attached to the core of metal atom or ion) (Figure 3) [3][11][12][16][19][21][22][23]. However, as reported by Awang et al., these anions usually behave in a bidentate manner [16].
Molecules 28 05841 g003 550
Figure 3. Different coordination modes of dithiocarbamate [22].

2. Synthesis of Organotin (IV) Dithiocarbamate

The in situ method has been proposed as the best way to prepare the dithiocarbamate compounds because the ligand cannot be synthesized in a solid form at a temperature above 4 °C [11]. The reaction between carbon disulfide and secondary amines is exothermic (heat release) during the production of dithiocarbamic acid [24][25]. Higher temperatures cause the ligand to break down, resulting in the formation of carbon dioxide, hydrogen sulfide, and ammonium thiocyanide [11]. Domazetis, Magee, and James (1977) prepared triphenyltin (IV) dithiocarbamate compounds using a low-temperature method, resulting in a good yield and high purity of compounds [21]. This shows that the temperature highly influences the form of the product. However, these complexes are very stable at ambient temperatures and begin to melt at temperatures exceeding 100 °C [11].

Previous studies reported that the yield using this method was greater than 50% [17][24][26][27][28][29][30]. Awang et al. and Muthalib and Baba noted in their studies that the dithiocarbamate ligands were synthesized by the nucleophilic addition of carbon disulfide to the corresponding amines in cold ethanol solutions (<4 °C) [31][32]. Generally, the addition of reagents (amines, bases, and carbon disulfide) for the synthesis of dithiocarbamates does not affect the product formed provided that the correct stoichiometric proportions are used [22]. The synthesis of the organotin (IV) dithiocarbamate complex was achieved by adding a defined amount of organotin (IV) chloride dropwise to a stirred mixture of ligands. The white precipitate that developed at the end of the process was filtered, washed with ethanol, and vacuum-dried in a desiccator over silica gel [31][32]. The compounds formed were washed with cold ethanol to remove unwanted residues from the desired product [22]. The narrow melting point intervals of approximately 1–2 °C indicated good compound purity [17]. 

3. Anticancer Effect of Organotin (IV) Dithiocarbamate

The FDA approval of cisplatin (Pt1) for the treatment of testicular cancer in 1978 caused a surge in interest in clinical metallodrugs and marked the beginning of medicinal inorganic chemistry [33]. However, cisplatin has significant side effects, including nephrotoxicity, hepatotoxicity, gastrotoxicity, myelosuppression, neurotoxicity, cardiotoxicity, and ototoxicity [34][35]. Therefore, researchers have focused on non-platinum chemotherapy drugs that have fewer side effects [36][37].
Recently, organotin (IV) dithiocarbamate complexes have received considerable attention because of their therapeutic potential. Both organotin and dithiocarbamate moieties have been found to play significant roles in the cytotoxic activities against various cancer cell lines [26]. Organotin compounds have potential as non-platinum chemotherapeutic drugs owing to their ability to exhibit fewer side effects, greater excretion abilities, higher antiproliferative activities, and lower toxicity than other platinum-based drugs [4][38][39][40]. Varela-Ramirez et al. [41] reported that although organotin has been implicated in important deleterious ecological effects, it is possible that by chemical modification, these compounds can be generated with fewer toxic side effects and higher antitumor activity. Therefore, more stable Sn-based compounds with different ligands have been synthesized and tested as potential cancer treatments.
Kamaludin et al. (2013) and Muhammad et al. (2022) claimed that organotin (IV) toxicity was directly correlated with the number and nature of organic moieties [17][42]. Highly substituted organotin compounds are more toxic, whereas shorter alkyl substituents enhance their cytotoxic effects [43][44][45]. In contrast, according to Adeyemi et al. (2020), longer chains of alkyl or aryl groups in organotin complexes cause more cytotoxicity than their shorter-chain counterparts. However, this trend can be a hindrance because of selectivity towards the cell lines used [26]. This could be because the toxicity trend, based on the length and nature of the substituents, depends on the target.
Organotin (IV) compounds with trialkyl and triaryl substituents are more toxic than those with dialkyl and aryl substitutions [24][31][38][46][47][48][49][50][51]. Di-substituted alkyl or aryl Sn(IV) groups showed a better cytotoxic effect compared to mono-substituted derivatives [49][52][53][54][55]. However, monosubstituted alkyl or aryl tin complexes may have good activity, especially butyl and phenyl derivatives [52], possibly because these complexes have exceptional cytotoxic capabilities. Table 1 shows the cytotoxicity of the organotin (IV) dithiocarbamate complexes against various human tumor cell lines (IC50 values). Compounds are considered highly toxic if their IC50 values are lower than 5.0 μg cm−3 (<8.70 μM) [17][56] (Table 2).
Table 1. In vitro cytotoxicity of the complexes against various human tumor cell lines (IC50).
Compound IC50 Values (μM) Tumor Cell Lines References
Dibutyltin (IV) N-butyl-N-phenyldithiocarbamate 0.8 Jurkat E6.1 [17]
Diphenyltin (IV) N-butyl-N-phenyldithiocarbamate 1.3
Triphenyltin (IV) N-butyl-N-phenyldithiocarbamate 0.4
Doxorubicin hydrochloride (control) 0.1
Dibutyltin (IV) N-butyl-N-phenyldithiocarbamate 5.3 K-562
Diphenyltin (IV) N-butyl-N-phenyldithiocarbamate 9.2
Triphenyltin (IV) N-butyl-N-phenyldithiocarbamate 1.9
Doxorubicin hydrochloride (control) 11.0
Triphenyltin (IV) benzylisopropyldithiocarbamate 0.18 Jurkat E6.1 [46]
Triphenyltin (IV) methylisopropyldithiocarbamate 0.03
Triphenyltin (IV) ethylisopropyldithiocarbamate 0.42
Etoposide (control) 0.12
MeSnClL2 >4000 HeLa [52]
BuSnClL2 8.12
PhSnClL2 4.37
Me2SnL2 12.30
Bu2SnL2 11.75
Ph2SnL2 0.01
5-Fluorouracil (control) 40
Dimethyltin (IV) benzyldithiocarbamate 40 Hela [26]
Dibutyltin (IV) benzyldithiocarbamate 0.019
Diphenyltin (IV) benzyldithiocarbamate 330
5-Fluorouracil (control) 40
Dimethyltin (IV) benzyldithiocarbamate 185 MCF-7
Dibutyltin (IV) benzyldithiocarbamate 57.3
Diphenyltin (IV) benzyldithiocarbamate 20
5-Fluorouracil (control) 56.2
Diphenyltin (IV) diallyldithiocarbamate 2.36 HT-29 [24]
Triphenyltin (IV) diallyldithiocarbamate 0.39
Ph3Sn(N,N-diisopropyldithiocarbamate) (OC2) 0.55 K562 [47]
Ph3Sn(N,N-diallyldithiocarbamate) (OC4) 1.1
Imatinib mesylate (control) 34
Diphenytin (IV) N-methyl-N-hydroxyethyldithiocarbamate 1.630 PC-3 [55]
4.937 Caco-2
Camptothecin (control) 24.41 PC-3
>100 Caco-2
Triphenyltin (IV) diisopropyldithiocarbamate (ODTC 3) 0.67 Jurkat E6.1 [48]
Triphenyltin (IV) diethyldithiocarbamate (ODTC 5) 0.92
Vincristine (control) 0.24
Table 2. Categories of toxicity levels of chemical compounds [56].
Category IC50 Value (μg cm−3)
Highly toxic <5.0
Moderately toxic 5.0 ≤≤ 10.0
Slightly toxic 10.0–25.0
Non-toxic >25.0
The lipophilicity of metal complexes is often affected by the nature of the alkyl or aryl groups on the tin metal core. For example, the phenyl group in an organotin molecule can facilitate π-π interactions with biomolecules [57], contributing to enhanced lipophilicity [52]. Previous research has shown that compounds containing phenyl groups have the highest cytotoxicity activity compared to the other series of complexes being studied, with the lowest IC50 value of 0.01 μM [26][38][52][58]. Adeyemi et al. [55] revealed that compounds containing more phenyl substituents possess a higher lipophilicity and thus exhibit a greater cytotoxic effect. This can be attributed to the reduction in the polarity surrounding the Sn metal center, which is ascribed to the decreased atomic dipole moment observed in the central Sn atom of the diphenyltin complex. Consequently, an increase in lipophilicity can enhance the permeability of the complex through cellular membranes.
Additionally, Adeyemi et al. reported that even though the diphenyltin complex is more effective than its mono-phenyl counterpart and conventional medication, it has indiscriminate effects on both healthy and cancer cell lines [55]. This may be attributed to chemical and anatomical barriers hindering the successful delivery of various micro/macromolecular compounds to their intended targets [59]. This issue can be resolved using drug carriers. Drugs carriers, for example nanomaterials, could amplify the potency of pharmaceuticals in cancer treatment. The application of stimuli-responsive systems, such as pH- and photo-responsive biomaterials, has exhibited efficacy in the transportation of drugs to specific target sites [59]. Recently, the green synthesis of nanoparticles using plant sources has also been explored. These biological methods are ecofriendly, consume less energy, and are cost-effective because they do not involve the use of toxic chemicals in their synthesis [60]. Notably, biosynthesized silver-nanoparticle-mediated Diospyros kaki L. (persimmon) showed potent cytotoxic effects on the studied cell lines [60]. Nanomaterials have long been utilized because of their remarkable potential to serve as effective carriers for delivering metal-based drugs, owing to their ability to protect active components from degradation, enhance their therapeutic properties, increase drug availability and specificity, and improve solubility [61]. These nanomaterials can release their contents within cells or in the extracellular environment for direct drug absorption and targeted action while preventing unwanted interactions with non-target tissues. When required, they prolong drug circulation and enable sustained drug release [62].
In a previous study conducted by Corvo et al. [63], the encapsulation of a cyclic trinuclear complex of Sn (IV) possessing an aromatic oximehydroxamic acid moiety (MG85) within PEGylated liposomes led to increased cancer cell death in colorectal carcinoma (HCT116) cells compared to the free complex, while concurrently decreasing cytotoxicity to non-tumor cells. Another study conducted by Paredes et al. [61] demonstrated the effectiveness of a nanotheranostic drug, MSN-AP-FA-PEP-S-Sn-AX (AX-3), in targeting and treating a triple-negative breast cancer cell line (MDA-MB-231). By combining receptor-mediated targeting with a specific release mechanism of the organotin metallodrug, AX-3 showed both diagnostic and therapeutic benefits while minimizing the toxic effects on the liver and kidneys upon repeated administration of the multifunctional nanodrug. This indicates that although organotin-based drugs show great promise, their limitations necessitate the use of suitable vectors for biomedical applications.
In addition, the cytotoxicity of the organotin (IV) complex is influenced by the dithiocarbamate ligand. Ligand systems have been reported to play significant roles in the lipophilicity and stability of metal complexes [64]. The presence of sulfur donor atoms in the dithiocarbamate ligand aids the transport of the metal complexes. The chelation effect due to the polarity of the Sn metal enhances biological activities [52] by increasing lipophilicity and facilitating the transportation of molecules to target sites [17][26][65]. Therefore, organotin (IV) compounds can interact with cellular and cytoplasmic membranes [66].
Previous studies have found that the activity of organotin (IV) antitumor compounds is influenced by several factors, including the stability of ligand–Sn bonds (such as Sn-N, Sn-S, and Sn-O), their slow hydrolytic decomposition [67], the structure of the molecule, and the coordination number of the Sn (IV) atoms [68]. Metal complexes formed by bidentate ligands such as dithiocarbamate form relatively stable molecules because of the chelation effect and the fact that the decomposition and loss of the ligand dithiocarbamate are not possible. In addition, the presence of a chelating dithiocarbamate should render the coordination of additional S-donor ligands (e.g., methionine and cysteine residues) trans to the -NCSS moiety less favorable because of the strong trans-influencing effect of the dithiocarbamate sulfur atoms. This may prevent further interactions of the metal center with other thiol-containing biomolecules, which are likely to cause severe side effects, such as nephrotoxicity [69][70]. Kadu et al. found that sulfur-containing compounds had better therapeutic indices in acidic environments; slightly acidic conditions are typically observed in solid tumors induced by the anaerobic fermentation of glucose-secreting lactic acid in tumor tissues [57].
Organotin-induced apoptosis may be the primary mechanism underlying organotin-induced cell death for organotin (IV) complexes [4][24][38][39][47][48][71]. Jakšić [72] proposed that organotins may induce apoptosis by causing changes in the cytoskeleton and disrupting mitochondrial functions. The apoptotic pathway is initiated by the interaction of organotins with cellular components, which can lead to the perturbation of intracellular Ca2+ homeostasis and increased [Ca 2+] uptake that leads to harmful effects for the mitochondrion, such as loss of mitochondrial membrane potential (ΔΨm), increased ROS production, followed by mitochondrial permeability transition (MPT) and membrane depolarization. The final ΔΨm degradation by MPT promotes the release of cytochrome c from the mitochondria into the cytosol, formation of the apoptosome, and subsequent activation of the initiator caspase-9 and executioner caspase-3, which execute the final steps of apoptosis.
Recent studies have reported the mechanism underlying the anti-proliferative effects of organotin (IV) dithiocarbamate in leukemia cells [47][48], which was supported by the observation of phosphatidylserine exposure on the plasma membrane [47]. Syed Annuar et al. [47] observed that the Ph3Sn(N,N-diisopropyldithiocarbamate) (OC2) complex triggered apoptosis in K562 cells via an intrinsic mitochondrial pathway that was activated by DNA damage, a crucial precursor of apoptosis. Subsequently, OC2 generated an overabundance of reactive oxygen species within the cell. The effect of this oxidative stress was confirmed by a notable decrease in both GSH levels and the percentage of apoptotic cells in the cells pretreated with NAC. Furthermore, research has indicated that organotin (IV) dithiocarbamate compounds can induce cell cycle arrest at different phases, including G0/G1, S, and S-G2/M [47][48]. Cell cycle arrest is crucial for the proper development and survival of multicellular organisms. This event is often triggered in response to the abnormal proliferation or harmful stressors, effectively preventing the spread of dysfunctional cells [73].
The interaction of organotin compounds with biomolecular proteins is influenced by their coordination geometry, biological properties, and presence of functional groups. It has been reported that compounds with a lower coordination number of Sn atoms (i.e., four) are more exposed to interactions with the donor atoms of the target cell biomolecules. Therefore, this complex has a higher anticancer activity [42]. In addition, organotin (IV) compounds exhibit electrophilic properties that enhance their interaction with the electron-donating groups of biomolecules [10], a trait similar to the aqueous form of cisplatin, which is a potent electrophile that reacts with a variety of nucleophiles, including nucleic acids and sulfhydryl groups of proteins [74]. The interaction of this compound with phosphorus-containing biomolecules, such as phospholipids, ATP, and nucleic acids, inhibits the synthesis of phospholipids and the intracellular transport of these biomolecules, thereby inducing the antiproliferative activity of the organotin (IV) derivative complex [10].
Organotin (IV) compounds have been shown to cause DNA damage by binding to the phosphate backbone of DNA, leading to contraction and changes in the DNA conformation [75][76]. The interaction of the organotin complex with DNA differs from that of cisplatin, which can bind to DNA via cross-linking [3]. Studies have shown that intercalation serves as the binding mode of organotin (IV) complexes with DNA [77][78][79]. The DNA-binding capability of organotin compounds is contingent upon factors such as the coordination number, nature of the alkyl groups attached to the central tin atom, and ligands attached to the organotin moiety [77]. According to previous reports, the planar complex exhibits the ability to easily intercalate DNA base pairs in cell lines [80]. Therefore, the complex may be highly cytotoxic. This argument is supported by phenyl-substituted compounds showing higher cytotoxicity than butyl- and methyl-substituted compounds due to the presence of planar phenyl group(s) within the organotin moiety, which enhances the lipophilicity of the complexes and their subsequent penetration into organisms [52]. Furthermore, organotin can inhibit cell division and proliferation by interacting with the nitrogenous bases of nucleic acid nucleotides, interfering with the replication and transcription of DNA molecules or affecting the multienzyme complexes responsible for the replication and transcription of DNA [81]. Hence, these complexes may target DNA, according to previous findings [4][31][39][49][52].

This entry is adapted from the peer-reviewed paper 10.3390/molecules28155841

References

  1. Rabiee, N.; Safarkhani, M.; Amini, M.M. Investigating the Structural Chemistry of Organotin(IV) Compounds: Recent Advances. Rev. Inorg. Chem. 2019, 39, 13–45.
  2. Ali, M.; Yousif, E. Chemistry and Applications of Organotin(IV) Complexes: A Review. Res. J. Pharm. Biol. Chem. Sci. 2016, 7, 2611–2619.
  3. Adeyemi, J.O.; Onwudiwe, D.C. Organotin(IV) Dithiocarbamate Complexes: Chemistry and Biological Activity. Molecules 2018, 23, 2571.
  4. Syed Annuar, S.N.; Kamaludin, N.F.; Awang, N.; Chan, K.M. Cellular Basis of Organotin(IV) Derivatives as Anticancer Metallodrugs: A Review. Front. Chem. 2021, 9, 657599.
  5. Iqbal, H.; Ali, S.; Shahzadi, S. Antituberculosis Study of Organotin(IV) Complexes: A Review. Cogent Chem. 2015, 1, 1029039.
  6. Sunday, A.O.; Alafara, B.A.; Oladele, O.G. Toxicity and Speciation Analysis of Organotin Compounds. Chem. Speciat. Bioavailab. 2012, 24, 216–226.
  7. Ayanda, O.S.; Fatoki, O.S.; Adekola, F.A.; Ximba, B.J. Fate and Remediation of Organotin Compounds in Seawaters and Soils. Chem. Sci. Trans. 2012, 1, 470–481.
  8. Pellerito, C.; Nagy, L.; Pellerito, L.; Szorcsik, A. Biological Activity Studies on Organotin(IV)N+ Complexes and Parent Compounds. J. Organomet. Chem. 2006, 691, 1733–1747.
  9. Carraher, C.E.; Roner, M.R. Organotin Polyethers as Biomaterials. Materials 2009, 2, 1558–1598.
  10. Awang, N.; Kamaludin, N.F.; Ghazali, A.R. Cytotoxic Effect of Organotin(IV) Benzylisopropyldithiocarbamate Compounds on Chang Liver Cell and Hepatocarcinoma HepG2 Cell. Pak. J. Biol. Sci. 2011, 14, 768–774.
  11. Kamaludin, N.F.; Awang, N. Synthesis and Characterisation of Organotin(IV) Nethyl- N-Phenyldithiocarbamate Compounds and the Crystal Structures of Dibutyl- And Triphenyltin(IV) Nethyl- N-Phenyldithiocarbamate. Res. J. Chem. Environ. 2014, 18, 90–98.
  12. Sainorudin, M.H.; Sidek, N.M.; Ismail, N.; Rozaini, M.Z.H.; Harun, N.A.; Tuan Anuar, T.N.S.; Azmi, A.A.A.R.; Yusoff, F. Synthesis, Characterization and Biological Activity of Organotin(IV) Complexes Featuring Di-2-Ethylhexyldithiocarbamate and N-Methylbutyldithiocarbamate as Ligands. GSTF J. Chem. Sci. 2015, 2, 2.
  13. Sharma, R.; Kaushik, N.K. Thermal Studies on Some Organotin(IV) Complexes with Piperidine and 2-Aminopyridine Dithiocarbamates. J. Therm. Anal. Calorim. 2004, 78, 953–964.
  14. Awang, N.; Baba, I. Diorganotin(IV) Alkylcyclohexyldithiocarbamate Compounds: Synthesis, Characterization and Biological Activities. Sains Malays. 2012, 41, 977–982.
  15. Fanjul-Bolado, P.; Fogel, R.; Limson, J.; Purcarea, C.; Vasilescu, A. Advances in the Detection of Dithiocarbamate Fungicides: Opportunities for Biosensors. Biosensors 2020, 11, 12.
  16. Awang, N.; Baba, I.; Yamin, B.M.; Halim, A.A. Preparation, Characterization and Antimicrobial Assay of 1,10-Phenanthroline and 2,2’-Bipyridyl Adducts of Cadmium(II) N-Sec-Butyl-N- Propyldithiocarbamate: Crystal Structure of Cd2(2,2’-Bipyridyl). World Appl. Sci. J. 2011, 12, 1568–1574.
  17. Kamaludin, N.F.; Awang, N.; Baba, I.; Hamid, A.; Meng, C.K. Synthesis, Characterization and Crystal Structure of Organotin(IV) N-Butyl-N-Phenyldithiocarbamate Compounds and Their Cytotoxicity in Human Leukemia Cell Lines. Pak. J. Biol. Sci. 2013, 16, 12–21.
  18. Nabipour, H.; Ghammamy, S.; Ashuri, S.; Aghbolagh, Z.S. Synthesis of a New Dithiocarbamate Compound and Study of Its Biological Properties. Org. Chem. J. 2010, 2, 75–80.
  19. Jung, O.-S.; Sohn, Y.-S. Coordination Chemistry of Organotin(IV) Dithiocarbamate Complexes. Bull. Korean Chem. Soc. 1988, 9, 365–368.
  20. Xu, L.Z.; Zhao, P.S.; Zhang, S.S. Crystal Structure and Characterization of Pd(II) Bis(Diisopropyldithiocarbamate) Complex. Chin. J. Chem. 2001, 19, 436–440.
  21. Domazetis, G.; Magee, R.J.; James, B.D. Synthesis and Structure of Some Triphenyltin(IV) Dithiocarbamate Compounds. J. Organomet. Chem. 1977, 141, 57–69.
  22. Odularu, A.T.; Ajibade, P.A. Dithiocarbamates: Challenges, Control, and Approaches to Excellent Yield, Characterization, and Their Biological Applications. Bioinorg. Chem. Appl. 2019, 2019, 826049.
  23. Onwudiwe, D.C.; Ajibade, P.A. Synthesis and Characterization of Metal Complexes of N-Alkyl-N-Phenyl Dithiocarbamates. Polyhedron 2010, 29, 1431–1436.
  24. Haezam, F.N.; Awang, N.; Kamaludin, N.F.; Mohamad, R. Synthesis and Cytotoxic Activity of Organotin(IV) Diallyldithiocarbamate Compounds as Anticancer Agent towards Colon Adenocarcinoma Cells (HT-29). Saudi J. Biol. Sci. 2021, 28, 3160–3168.
  25. Baba, I.; Raya, I. Kompleks Praseodimium Ditiokarbamat 1,10 Fenantrolin. Sains Malays. 2010, 39, 45–50.
  26. Adeyemi, J.O.; Onwudiwe, D.C.; Nundkumar, N.; Singh, M. Diorganotin(IV) Benzyldithiocarbamate Complexes: Synthesis, Characterization, and Thermal and Cytotoxicity Study. Open Chem. 2020, 18, 453–462.
  27. Adeyemi, J.O.; Onwudiwe, D.C.; Hosten, E.C. Organotin(IV) Complexes Derived from N-Ethyl-N-Phenyldithiocarbamate: Synthesis, Characterization and Thermal Studies. J. Saudi Chem. Soc. 2018, 22, 427–438.
  28. Adeyemi, J.O.; Onwudiwe, D.C.; Hosten, E.C. Synthesis, Characterization and the Use of Organotin(IV) Dithiocarbamate Complexes as Precursor to Tin Sulfide Nanoparticles by Heat up Approach. J. Mol. Struct. 2019, 1195, 395–402.
  29. Adli, H.K.; Sidek, N.M.; Ismail, N.; Khairul, W.M. Several Organotin (IV) Complexes Featuring 1-Methylpiperazinedithiocarbamate and N-Methylcyclohexyldithiocarbamate as Ligands and Their Anti-Microbial Activity Studies. Chiang Mai J. Sci. 2013, 40, 117–125.
  30. Mohamad, R.; Awang, N.; Farahana Kamaludin, N. Synthesis and Characterisation of New Organotin (IV)(2-Methoxyethyl)-Methyldithiocarbamate Complexes. Res. J. Pharm. Biol. Chem. Sci. 2016, 7, 1920–1925.
  31. Awang, N.; Baba, I.; Yamin, B.M.; Othman, M.S.; Kamaludin, N.F. Synthesis, Characterization and Biological Activities of Organotin (IV) Methylcyclohexyldithiocarbamate Compounds. Am. J. Appl. Sci. 2011, 8, 310–317.
  32. Muthalib, A.F.A.; Baba, I. New Mono-Organotin (IV) Dithiocarbamate Complexes. In Proceedings of the AIP Conference Proceedings, Selangor, Malaysia, 9–11 April 2014; Volume 1614, pp. 237–243.
  33. Anthony, E.J.; Bolitho, E.M.; Bridgewater, H.E.; Carter, O.W.L.; Donnelly, J.M.; Imberti, C.; Lant, E.C.; Lermyte, F.; Needham, R.J.; Palau, M.; et al. Metallodrugs Are Unique: Opportunities and Challenges of Discovery and Development. Chem. Sci. 2020, 11, 12888–12917.
  34. Dasari, S.; Bernard Tchounwou, P. Cisplatin in Cancer Therapy: Molecular Mechanisms of Action. Eur. J. Pharmacol. 2014, 740, 364–378.
  35. Oun, R.; Moussa, Y.E.; Wheate, N.J. The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists. Dalton Trans. 2018, 47, 6645–6653.
  36. Hadi, A.G.; Jawad, K.; Ahmed, D.S.; Yousif, E. Synthesis and Biological Activities of Organotin (IV) Carboxylates: A Review. Syst. Rev. Pharm. 2019, 10, 26–31.
  37. Gielen, M. Organotin Compounds and Their Therapeutic Potential: A Report from the Organometallic Chemistry Department of the Free University of Brussels. Appl. Organomet. Chem. 2002, 16, 481–494.
  38. Hamid, A.; Azmi, M.A.; Rajab, N.F.; Awang, N.; Jufri, N.F. Cytotoxic Effects of Organotin(IV) Dithiocarbamate Compounds with Different Functional Groups on Leukemic Cell Line, K-562. Sains Malays. 2020, 49, 1421–1430.
  39. Attanzio, A.; D’Agostino, S.; Busà, R.; Frazzitta, A.; Rubino, S.; Girasolo, M.A.; Sabatino, P.; Tesoriere, L. Cytotoxic Activity of Organotin(IV) Derivatives with Triazolopyrimidine Containing Exocyclic Oxygen Atoms. Molecules 2020, 25, 859.
  40. Gómez-Ruiz, S.; Kaluderović, G.N.; Prashar, S.; Hey-Hawkins, E.; Erić, A.; Žižak, Ž.; Juranić, Z.D. Study of the Cytotoxic Activity of Di and Triphenyltin(IV) Carboxylate Complexes. J. Inorg. Biochem. 2008, 102, 2087–2096.
  41. Varela-Ramirez, A.; Costanzo, M.; Carrasco, Y.P.; Pannell, K.H.; Aguilera, R.J. Cytotoxic Effects of Two Organotin Compounds and Their Mode of Inflicting Cell Death on Four Mammalian Cancer Cells. Cell Biol. Toxicol. 2011, 27, 159–168.
  42. Muhammad, N.; Ahmad, M.; Sirajuddin, M.; Ali, Z.; Tumanov, N.; Wouters, J.; Chafik, A.; Solak, K.; Mavi, A.; Muhammad, S.; et al. Synthesis, Characterization, Biological Activity and Molecular Docking Studies of Novel Organotin(IV) Carboxylates. Front. Pharmacol. 2022, 13, 864336.
  43. Koch, B.; Basu Baul, T.S.; Chatterjee, A. P53-Dependent Antiproliferative and Antitumor Effect of Novel Alkyl Series of Diorganotin(IV) Compounds. Investig. New Drugs 2009, 27, 319–326.
  44. Ray, D.; Sarma, K.D.; Antony, A. Differential Effects of Tri-n-Butylstannyl Benzoates on Induction of Apoptosis in K562 and MCF-7 Cells. IUBMB Life 2000, 49, 519–525.
  45. Wada, O.; Manabe, S.; Iwai, H.; Arakawa, Y. Recent Progress in the Study of Analytical Methods, Toxicity, Metabolism and Health Effects of Organotin Compounds. Sangyo Igaku 1982, 24, 24–54.
  46. Awang, N.; Yousof, N.S.A.M.; Rajab, N.F.; Kamaludin, N.F. In Vitro Cytotoxic Activity of New Triphenyltin (IV) Alkyl-Isopropyldi-Thiocarbamate Compounds on Human Acute T-Lymphoblastic Cell Line. J. Appl. Pharm. Sci. 2015, 5, 7–11.
  47. Syed Annuar, S.N.; Kamaludin, N.F.; Awang, N.; Chan, K.M. Triphenyltin(IV) Dithiocarbamate Compound Induces Genotoxicity and Cytotoxicity in K562 Human Erythroleukemia Cells Primarily via Mitochondria-Mediated Apoptosis. Food Chem. Toxicol. 2022, 168, 113336.
  48. Rasli, N.R.; Hamid, A.; Awang, N.; Kamaludin, N.F. Series of Organotin(IV) Compounds with Different Dithiocarbamate Ligands Induced Cytotoxicity, Apoptosis and Cell Cycle Arrest on Jurkat E6.1, T Acute Lymphoblastic Leukemia Cells. Molecules 2023, 28, 3376.
  49. Adeyemi, J.O.; Onwudiwe, D.C.; Ekennia, A.C.; Okafor, S.N.; Hosten, E.C. Organotin(IV)N-Butyl-N-Phenyldithiocarbamate Complexes: Synthesis, Characterization, Biological Evaluation and Molecular Docking Studies. J. Mol. Struct. 2019, 1192, 15–26.
  50. Awang, N.; Kamaludin, N.F.; Baba, I.; Chan, K.M.; Rajaajab, N.F.; Hamid, A. Synthesis, Characterization and Antitumor Activity of New Organotin(IV) Methoxyethyldithiocarbamate Complexes. Orient. J. Chem. 2016, 32, 101–107.
  51. Nath, M. Toxicity and the Cardiovascular Activity of Organotin Compounds: A Review. Appl. Organomet. Chem. 2008, 22, 598–612.
  52. Adeyemi, J.O.; Onwudiwe, D.C. Antimicrobial and Cytotoxicity Studies of Some Organotin(IV) N-Ethyl-N-Phenyl Dithiocarbamate Complexes. Pol. J. Environ. Stud. 2020, 29, 2525–2532.
  53. Adeyemi, J.O.; Onwudiwe, D.C.; Singh, M. Synthesis, Characterization, and Cytotoxicity Study of Organotin(IV) Complexes Involving Different Dithiocarbamate Groups. J. Mol. Struct. 2019, 1179, 366–375.
  54. Tiekink, E.R.T. Tin Dithiocarbamates: Applications and Structures. Appl. Organomet. Chem. 2008, 22, 533–550.
  55. Adeyemi, J.O.; Olasunkanmi, L.O.; Fadaka, A.O.; Sibuyi, N.R.S.; Oyedeji, A.O.; Onwudiwe, D.C. Synthesis, Theoretical Calculation, and Biological Studies of Mono-and Diphenyltin(IV) Complexes of N-Methyl-N-Hydroxyethyldithiocarbamate. Molecules 2022, 27, 2947.
  56. How, F.N.-F.; Crouse, K.A.; Tahir, M.I.M.; Tarafder, M.T.H.; Cowley, A.R. Synthesis, Characterization and Biological Studies of S-Benzyl-β-N-(Benzoyl) Dithiocarbazate and Its Metal Complexes. Polyhedron 2008, 27, 3325–3329.
  57. Kadu, R.; Roy, H.; Singh, V.K. Diphenyltin(IV) Dithiocarbamate Macrocyclic Scaffolds as Potent Apoptosis Inducers for Human Cancer HEP 3B and IMR 32 Cells: Synthesis, Spectral Characterization, Density Functional Theory Study and in Vitro Cytotoxicity. Appl. Organomet. Chem. 2015, 29, 746–755.
  58. Awang, N.; Baba, I.; Mohd Yousof, N.S.A.; Kamaludin, N.F. Synthesis and Characterization of Organotin(IV) N-Benzyl-N-Isopropyldithiocarbamate Compounds: Cytotoxic Assay on Human Hepatocarcinoma Cells (HepG2). Am. J. Appl. Sci. 2010, 7, 1047–1052.
  59. Khalilov, R. A Comprehensive Review of Advanced Nano-Biomaterials in Regenerative Medicine and Drug Delivery. Adv. Biol. Earth Sci. 2023, 8, 5–18.
  60. Keskin, C.; Ölçekçi, A.; Baran, A.; Baran, M.F.; Eftekhari, A.; Omarova, S.; Khalilov, R.; Aliyev, E.; Sufianov, A.; Beilerli, A.; et al. Green Synthesis of Silver Nanoparticles Mediated Diospyros Kaki L. (Persimmon): Determination of Chemical Composition and Evaluation of Their Antimicrobials and Anticancer Activities. Front. Chem. 2023, 11, 1187808.
  61. Paredes, K.O.; Díaz-García, D.; García-Almodóvar, V.; Chamizo, L.L.; Marciello, M.; Díaz-Sánchez, M.; Prashar, S.; Gómez-Ruiz, S.; Filice, M. Multifunctional Silica-Based Nanoparticles with Controlled Release of Organotin Metallodrug for Targeted Theranosis of Breast Cancer. Cancers 2020, 12, 187.
  62. van der Koog, L.; Gandek, T.B.; Nagelkerke, A. Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization. Adv. Healthc. Mater. 2022, 11, e2100639.
  63. Corvo, M.L.; Mendo, A.S.; Figueiredo, S.; Gaspar, R.; Larguinho, M.; Guedes da Silva, M.F.C.; Baptista, P.V.; Fernandes, A.R. Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy. Pharm. Res. 2016, 33, 1351–1358.
  64. Galanski, M.S.; Jakupec, M.A.; Keppler, B.K. Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Curr. Med. Chem. 2005, 12, 2075–2094.
  65. Cvek, B.; Dvorak, Z. Targeting of Nuclear Factor-KappaB and Proteasome by Dithiocarbamate Complexes with Metals. Curr. Pharm. Des. 2007, 13, 3155–3167.
  66. Iqbal, H.; Ali, S.; Shahzadi, S. Anti-Inflammatory and Acute Toxicity Study of Organotin (IV) Complexes: A Review. Chem. J. 2016, 6, 59–73.
  67. Iqbal, M.; Ali, S.; Haider, A.; Khalid, N. Therapeutic Properties of Organotin Complexes with Reference to Their Structural and Environmental Features. Rev. Inorg. Chem. 2017, 37, 51–70.
  68. Ahmad Shah, S.S.; Ashfaq, M.; Waseem, A.; Ahmed, M.M.; Najam, T.; Shaheen, S.; Rivera, G. Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review. Mini Rev. Med. Chem. 2015, 15, 406–426.
  69. Adokoh, C.K. Therapeutic Potential of Dithiocarbamate Supported Gold Compounds. RSC Adv. 2020, 10, 2975–2988.
  70. Cattaruzza, L.; Fregona, D.; Mongiat, M.; Ronconi, L.; Fassina, A.; Colombatti, A.; Aldinucci, D. Antitumor Activity of Gold(III)-Dithiocarbamato Derivatives on Prostate Cancer Cells and Xenografts. Int. J. Cancer 2011, 128, 206–215.
  71. Kamaludin, N.F.; Ismail, N.; Awang, N.; Mohamad, R.; Pim, N.U. Cytotoxicity Evaluation and the Mode of Cell Death of K562 Cells Induced by Organotin (IV) (2-Methoxyethyl) Methyldithiocarbamate Compounds. J. Appl. Pharm. Sci. 2019, 9, 10–15.
  72. Jakšić, Ž. Mechanisms of Organotin-Induced Apoptosis. In Biochemical and Biological Effects of Organotins; Bentham Science: Sharjah, United Arab Emirates, 2012; pp. 149–163.
  73. Kumari, R.; Jat, P. Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. Front. Cell Dev. Biol. 2021, 9, 645593.
  74. Basu, A.; Krishnamurthy, S. Cellular Responses to Cisplatin-Induced DNA Damage. J. Nucleic Acids 2010, 2010, 201367.
  75. Yusof, E.N.M.; Latif, M.A.M.; Tahir, M.I.M.; Sakoff, J.A.; Simone, M.I.; Page, A.J.; Veerakumarasivam, A.; Tiekink, E.R.T.; Ravoof, T.B.S.A. O-Vanillin Derived Schiff Bases and Their Organotin(Iv) Compounds: Synthesis, Structural Characterisation, in-Silico Studies and Cytotoxicity. Int. J. Mol. Sci. 2019, 20, 854.
  76. Arjmand, F.; Parveen, S.; Tabassum, S.; Pettinari, C. Organo-Tin Antitumor Compounds: Their Present Status in Drug Development and Future Perspectives. Inorganica Chim. Acta 2014, 423, 26–37.
  77. Devi, J.; Pachwania, S. Recent Advancements in DNA Interaction Studies of Organotin(IV) Complexes. Inorg. Chem. Commun. 2018, 91, 44–62.
  78. Sirajuddin, M.; Ali, S.; Haider, A.; Shah, N.A.; Shah, A.; Khan, M.R. Synthesis, Characterization, Biological Screenings and Interaction with Calf Thymus DNA as Well as Electrochemical Studies of Adducts Formed by Azomethine and Organotin(IV) Chlorides. Polyhedron 2012, 40, 19–31.
  79. Hussain, S.; Ali, S.; Shahzadi, S.; Tahir, M.N.; Shahid, M. Synthesis, Characterization, Single Crystal XRD and Biological Screenings of Organotin(IV) Derivatives with 4-(2-Hydroxyethyl)Piperazine-1-Carbodithioic Acid. J. Coord. Chem. 2016, 69, 687–703.
  80. Liu, K.; Yan, H.; Chang, G.; Li, Z.; Niu, M.; Hong, M. Organotin(IV) Complexes Derived from Hydrazone Schiff Base: Synthesis, Crystal Structure, in Vitro Cytotoxicity and DNA/BSA Interactions. Inorganica Chim. Acta 2017, 464, 137–146.
  81. Shaheen, F.; Sirajuddin, M.; Ali, S.; Zia-ur-Rehman; Dyson, P.J.; Shah, N.A.; Tahir, M.N. Organotin(IV) 4-(BenzoDioxol-5-Ylmethyl)Piperazine-1-Carbodithioates: Synthesis, Characterization and Biological Activities. J. Organomet. Chem. 2018, 856, 13–22.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback